Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Panbela Therapeutics Inc (NQ: PBLA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Panbela Therapeutics Inc

< Previous 1 2 3 Next >
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Developed in collaboration with Sanofi. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial's lower-than-expected event rate suggests improved survival outcomes 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Poster Presentation at American Association for Cancer Research:
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Transfer to OTCQB Market
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
From Panbela Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Secures ~$9M in Public Offering
Via Investor Brand Network
Panbela Announces Closing of Approximately $9.0 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.0 Million Gross Proceeds Priced At-the-Market
From Panbela Therapeutics, Inc.
Via GlobeNewswire
PRISM Biotech in Motion: FDA Approval for Panbela Therapeutics Pediatric Cancer Drug; Shares Jump 120%
Via AB Newswire
Exposures Product Safety
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Publication of Abstract Titled: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Validation of European Patent in UK, Italy, Germany, France, and Spain for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Present at the LD Micro Investor Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
Patent developed in collaboration with Sanofi 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.